Evidence map›Paper›PMID 18021445›Full record

ArticleBMC cancer2007

Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest.

Sharon Sheahan, Christopher O Bellamy, Donald R Dunbar, David J Harrison, Sandrine Prost

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  7. Article
  8. Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma.International journal of clinical and experimental pathology · 2013
    Article
  9. Article
  10. Bone morphogenetic protein 4 (BMP4) signaling in retinoblastoma cells.International journal of biological sciences · 2010
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Antagonistic pleiotropy and p53.Mechanisms of ageing and development
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sharon SheahanDivision of Pathology, Queen's Medical Research Institute, Edinburgh, UK. sheahan@hotmail.com
Christopher O Bellamy
Donald R Dunbar
David J Harrison
Sandrine Prost
The Queen's Medical Research Institute · GBEdinburgh Royal Infirmary · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundTGFbeta is critical to control hepatocyte proliferation by inducing G1-growth arrest through multiple pathways leading to inhibition of E2F transcription activity. The retinoblastoma protein pRb is a key controller of E2F activity and G1/S transition which can be inhibited in viral hepatitis. It is not known whether the impairment of pRb would alter the growth inhibitory potential of TGFbeta in disease. We asked how Rb-deficiency would affect responses to TGFbeta-induced cell cycle arrest.

resultsPrimary hepatocytes isolated from Rb-floxed mice were infected with an adenovirus expressing CRE-recombinase to delete the Rb gene. In control cells treatment with TGFbeta prevented cells to enter S phase via decreased cMYC activity, activation of P16INK4A and P21Cip and reduction of E2F activity. In Rb-null hepatocytes, cMYC activity decreased slightly but P16INK4A was not activated and the great majority of cells continued cycling. Rb is therefore central to TGFbeta-induced cell cycle arrest in hepatocytes. However some Rb-null hepatocytes remained sensitive to TGFbeta-induced cell cycle arrest. As these hepatocytes expressed very high levels of P21Cip1 and P53 we investigated whether these proteins regulate pRb-independent signaling to cell cycle arrest by evaluating the consequences of disruption of p53 and p21Cip1. Hepatocytes deficient in p53 or p21Cip1 showed diminished growth inhibition by TGFbeta. Double deficiency had a similar impact showing that in cells containing functional pRb; P21Cip and P53 work through the same pathway to regulate G1/S in response to TGFbeta. In Rb-deficient cells however, p53 but not p21Cip deficiency had an additive effect highlighting a pRb-independent-P53-dependent effector pathway of inhibition of E2F activity.

conclusionThe present results show that otherwise genetically normal hepatocytes with disabled p53, p21Cip1 or Rb genes respond less well to the antiproliferative effects of TGFbeta. As the function of these critical cellular proteins can be impaired by common causes of chronic liver disease and HCC, including viral hepatitis B and C proteins, we suggest that disruption of pRb function, and to a lesser extend P21Cip1 and P53 in hepatocytes may represent an additional new mechanism of escape from TGFbeta-growth-inhibition in the inflammatory milieu of chronic liver disease and contribute to cancer development.

Indexed as

AnimalsCell CycleCell ProliferationCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21E2F Transcription FactorsFluorescent Antibody TechniqueHepatocytesMaleMiceMice, KnockoutProto-Oncogene Proteins c-mycRetinoblastoma ProteinSignal TransductionTransforming Growth Factor betaTumor Suppressor Protein p53Cdkn1a protein, mouseCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21E2F Transcription FactorsMyc protein, mouseProto-Oncogene Proteins c-mycRetinoblastoma ProteinTransforming Growth Factor betaTumor Suppressor Protein p53

Identifiers

PMID18021445
PMCPMC2206047
OpenAlexW2169344604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.